2024-04-04 00:56:46 ET
Summary
- Novartis is now a pure player in innovative medicines.
- Despite a negative FX, the company reported solid 2023 financial results and increased its dividend per share.
- There is a strategic rationale for acquiring MorphoSys AG. NVS had raised its outlook for three quarters in a row. We have now moved our rating to buy.
Following the Sandoz spin-off and Alcon sale, Novartis ( NVS ) (NVSEF) has completed a big step in its transformation into a pure-play in innovative medicines ( Fig 1 )....
Read the full article on Seeking Alpha
For further details see:
Novartis: Higher Guidance, Now A Buy